Trial Details

COMPLETED
Basic Information
Clinical ID c785
Identifier NCT06055023
Trial Title Phase I Clinical Study of ZL-82 Tablets
Trial URL Visit Original Page
Study Information
Study Results

NO
Conditions Rheumatoid Arthritis (RA)|Inflammatory Bowel Disease - IBD1
Interventions DRUG: ZL-82 12.5mg|DRUG: ZL-82 25mg|DRUG: ZL-82 50mg|DRUG: ZL-82 100mg|DRUG: ZL-82 200mg|DRUG: ZL-82 300mg|DRUG: ZL-82 450mg|DRUG: ZL-82 600mg|DRUG: zL-82 placebo 12.5mg|DRUG: ZL-82 placebo 25mg|DRUG: ZL-82 placebo 50mg|DRUG: ZL-82 placebo 100mg|DRUG: ZL-82 placebo 200mg|DRUG: ZL-82 placebo 300mg|DRUG: ZL-82 placebo 450mg|DRUG: ZL-82 placebo 600mg
Participant Information
Sponsor Chengdu Zenitar Biomedical Technology Co., Ltd
City GuiYang
Country/Region China
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2023-04-09
Primary Completion Date 2024-01-28
Completion Date 2024-06-13